日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells

通过靶向共价沉积在淋巴瘤细胞上的补体C3片段来增强CD20单克隆抗体疗法的疗效

Baskar, Sivasubramanian; Peng, Haiyong; Gaglione, Erika M; Carstens, Elizabeth J; Lindorfer, Margaret A; Ahn, Inhye E; Herman, Sarah E M; Skarzynski, Martin; Chang, Jing; Keyvanfar, Keyvan; Butera, Vicent; Blackburn, Amy; Vire, Bérengère; Maric, Irina; Stetler-Stevenson, Maryalice; Yuan, Constance M; Eckhaus, Michael A; Soto, Susan; Farooqui, Mohammed Z H; Taylor, Ronald P; Rader, Christoph; Wiestner, Adrian

Inhibition of Complement Will Substantially Reduce the Anemia of Malaria

抑制补体可显著降低疟疾引起的贫血

Taylor, Ronald P; Lindorfer, Margaret A

Phagocytosis via complement receptor 3 enables microbes to evade killing by neutrophils.

微生物通过补体受体 3 的吞噬作用逃避中性粒细胞的杀灭

Smirnov Asya, Daily Kylene P, Gray Mary C, Ragland Stephanie A, Werner Lacie M, Brittany Johnson Morgan, Eby Joshua C, Hewlett Erik L, Taylor Ronald P, Criss Alison K

Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions

利妥昔单抗诱导的细胞因子释放伴高血清IP-10(CXCL10)浓度与输注反应相关。

Moore, Jeremiah E; Bloom, Paige C; Chu, Charles C; Bruno, Jennifer E; Herne, Christine A; Baran, Andrea M; Quataert, Sally A; Mosmann, Timothy R; Taylor, Ronald P; Wallace, Danielle S; Elliott, Michael R; Barr, Paul M; Zent, Clive S

FcγR-Mediated Trogocytosis 2.0: Revisiting History Gives Rise to a Unifying Hypothesis

FcγR介导的吞噬作用2.0:回顾历史,得出统一的假说

Lindorfer, Margaret A; Taylor, Ronald P

Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study

风险适应性、基于奥法妥木单抗的化疗免疫疗法和巩固疗法治疗初治慢性淋巴细胞白血病:一项 II 期研究

Desai, Sanjal; Mo, Clifton; Gaglione, Erika M; Yuan, Constance M; Stetler-Stevenson, Maryalice; Tian, Xin; Maric, Irina; Wake, Laura; Farooqui, Mohammed Z; Drinkwater, Dennis C; Soto, Susan; Valdez, Janet; Hughes, Thomas E; Nierman, Pia; Lotter, Jennifer; Marti, Gerald E; Pleyer, Christopher; Sun, Clare; Superata, Jeanine; Nichols, Cydney; Herman, Sarah E M; Lindorfer, Margaret A; Taylor, Ronald P; Wiestner, Adrian; Ahn, Inhye E

Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome.

补体因子 B 的突变导致替代补体途径的大量液相失调,可导致非典型溶血性尿毒综合征

Zhang Yuzhou, Kremsdorf Robin A, Sperati C John, Henriksen Kammi J, Mori Mari, Goodfellow Renee X, Pitcher Gabriella R, Benson Cindy L, Borsa Nicolo Ghiringhelli, Taylor Ronald P, Nester Carla M, Smith Richard J H

DuoHexaBody-CD37(®), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies

DuoHexaBody-CD37® 是一种新型双位点 CD37 抗体,具有增强的 Fc 介导的六聚化作用,有望成为 B 细胞恶性肿瘤的潜在治疗方法。

Oostindie, Simone C; van der Horst, Hilma J; Kil, Laurens P; Strumane, Kristin; Overdijk, Marije B; van den Brink, Edward N; van den Brakel, Jeroen H N; Rademaker, Hendrik J; van Kessel, Berris; van den Noort, Juliette; Chamuleau, Martine E D; Mutis, Tuna; Lindorfer, Margaret A; Taylor, Ronald P; Schuurman, Janine; Parren, Paul W H I; Beurskens, Frank J; Breij, Esther C W

Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes

利用与红细胞结合的双特异性抗体构建体清除β-淀粉样蛋白

Taylor, Ronald P; Lindorfer, Margaret A; Atkinson, John P

How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca(2)

单克隆抗体如何利用补体杀死癌细胞?Ca(2)的作用

Taylor, Ronald P; Lindorfer, Margaret A